A new report says the White House is reviewing the next FDA prescription drug user fee deal covering 2028–2032, setting up a key policy lever for how much authority the agency and industry will share for the drug review pipeline. The decision could influence review timelines and operational targets that drive the next cycle of clinical development planning. Separately, commentary and policy coverage at the Pricing and Contracting USA event highlighted CMS’s push for more direct engagement with pharma on Most Favored Nation (MFN) and related pricing strategy, emphasizing earlier conversations rather than waiting for later compliance questions. Together, the items point to regulators and payers tightening how companies structure market access and early development planning, with engagement moving upstream in both review and pricing.